Optomed Oyj Future Growth

Future criteria checks 2/6

Optomed Oyj wird ein jährliches Wachstum der Erträge und Einnahmen um 60.4% bzw. 22.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 61.2% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -17.9% betragen.

Key information

62.3%

Earnings growth rate

62.8%

EPS growth rate

Medical Equipment earnings growth22.2%
Revenue growth rate22.4%
Future return on equity-18.5%
Analyst coverage

Low

Last updated06 Mar 2024

Recent future growth updates

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Feb 18
Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Recent updates

Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Mar 22
Market Might Still Lack Some Conviction On Optomed Oyj (HEL:OPTOMED) Even After 25% Share Price Boost

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Feb 18
Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Dec 21
Market Cool On Optomed Oyj's (HEL:OPTOMED) Revenues

Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Nov 15
Is Optomed Oyj (HEL:OPTOMED) Using Debt In A Risky Way?

Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Aug 09
Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Jun 01
Investors Continue Waiting On Sidelines For Optomed Oyj (HEL:OPTOMED)

Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Oct 27
Does Optomed Oyj (HEL:OPTOMED) Have A Healthy Balance Sheet?

Is Optomed Oyj (HEL:OPTOMED) A Risky Investment?

Apr 23
Is Optomed Oyj (HEL:OPTOMED) A Risky Investment?

Optomed Oyj (HEL:OPTOMED) Has Debt But No Earnings; Should You Worry?

Aug 05
Optomed Oyj (HEL:OPTOMED) Has Debt But No Earnings; Should You Worry?

The Optomed Oyj (HEL:OPTOMED) Share Price Has Gained 14% And Shareholders Are Hoping For More

Feb 16
The Optomed Oyj (HEL:OPTOMED) Share Price Has Gained 14% And Shareholders Are Hoping For More

Earnings and Revenue Growth Forecasts

HLSE:OPTOMED - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026300021
12/31/202525-3-3-13
12/31/202417-4-5-32
12/31/202315-4-3-1N/A
9/30/202315-4-30N/A
6/30/202315-5-4-2N/A
3/31/202315-5-5-2N/A
12/31/202215-5-5-2N/A
9/30/202214-6-6-3N/A
6/30/202214-5-6-3N/A
3/31/202214-5-6-3N/A
12/31/202115-4-6-3N/A
9/30/202115-3-4-2N/A
6/30/202115-2-4-2N/A
3/31/202114-3-20N/A
12/31/202013-3-5-3N/A
9/30/202013-3-3-1N/A
6/30/202013-4-3-1N/A
3/31/202015-4-4-2N/A
12/31/201915-3-10N/A
9/30/201916-2-20N/A
12/31/201814-1-20N/A
12/31/20177-3-3-1N/A
12/31/20167-3N/A-1N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: OPTOMED wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: OPTOMED wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: OPTOMED wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: OPTOMEDDie Einnahmen des Unternehmens (25.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Finnish (2.7% pro Jahr).

Hohe Wachstumseinnahmen: OPTOMEDDie Einnahmen des Unternehmens (25.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.


Earnings per Share Growth Forecasts


Future Return on Equity

Künftige Eigenkapitalrendite: OPTOMED wird voraussichtlich in 3 Jahren unrentabel sein.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.